Allan, J. N., Pinilla-Ibarz, J., Gladstone, D. E., Patel, K., Sharman, J. P., Wierda, W. G., Choi, M. Y., O’Brien, S. M., Shadman, M., Davids, M. S., Pagel, J. M., Yimer, H. A., Ward, R., Acton, G., Taverna, P., Combs, D. L., Fox, J. A., Furman, R. R. and Brown, J. R. (2022) “Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies”, Haematologica. Pavia, Italy, 107(4), pp. 984-987. doi: 10.3324/haematol.2021.280061.